UB Paderborn / Katalog / Suche / in CDI

Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Journal of Alzheimer's disease, 2015-01, Vol.48 (2), p.403

2015

Volltextzugriff (PDF)

Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers

Journal of Alzheimer's disease, 2013-01, Vol.35 (4), p.697

2013

Volltextzugriff (PDF)

DHA-rich n–3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study

The American journal of clinical nutrition, 2017-10, Vol.106 (4), p.1157-1165

2017

Volltextzugriff (PDF)

Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia

Journal of Alzheimer's disease, 2013-01, Vol.33 (1), p.45

2013

Volltextzugriff (PDF)

Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study

PloS one, 2012-04, Vol.7 (4), p.e35425-e35425

2012

Volltextzugriff (PDF)

Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study

The American journal of clinical nutrition, 2008-06, Vol.87 (6), p.1616-1622

2008

Volltextzugriff (PDF)

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms

International journal of geriatric psychiatry, 2008-02, Vol.23 (2), p.161-169

2008

Volltextzugriff (PDF)

Performance on a pattern separation task by Alzheimer's patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels

Alzheimer's research & therapy, 2014, Vol.6 (2), p.20-20

2014

Volltextzugriff (PDF)

Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia

Journal of Alzheimer's disease, 2013-01, Vol.34 (3), p.673

2013

Volltextzugriff (PDF)

Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls

Journal of Alzheimer's disease, 2010-01, Vol.22 (4), p.1223

2010

Volltextzugriff (PDF)

Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study

Dementia and geriatric cognitive disorders, 2009-01, Vol.27 (5), p.481

2009

Volltextzugriff (PDF)

Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study

Journal of Alzheimer's disease, 2009-01, Vol.18 (1), p.79

2009

Volltextzugriff (PDF)

Reduced prostaglandin F2α release from blood mononuclear leukocytes after oral supplementation of ω3 fatty acids: the OmegAD study

Journal of lipid research, 2010-05, Vol.51 (5), p.1179-1185

2010

Volltextzugriff (PDF)

Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease

Current Alzheimer research, 2011-12, Vol.8 (8), p.853

2011

Volltextzugriff (PDF)

Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody

Alzheimer's research & therapy, 2016-04, Vol.8 (1), p.14, Article 14

2016

Volltextzugriff (PDF)

Transfer of omega‐3 fatty acids across the blood–brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study

Journal of internal medicine, 2014-04, Vol.275 (4), p.428-436

2014

Volltextzugriff (PDF)

Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study

The journal of clinical psychiatry, 2009-06, Vol.70 (6), p.922

2009

Volltextzugriff (PDF)

Porous graphitic carbon chromatography–tandem mass spectrometry for the study of isoprostanes in human cerebrospinal fluid

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2005-11, Vol.827 (1), p.39-43

2005

Volltextzugriff (PDF)

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Molecular and cellular neuroscience, 2021-07, Vol.114, p.103641-103641, Article 103641

2021

Volltextzugriff (PDF)

Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study

Journal of Alzheimer's disease, 2015-01, Vol.48 (3), p.805

2015

Volltextzugriff (PDF)

Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trial-The OmegAD Study

Journal of Alzheimer's disease, 2021-01, Vol.83 (3), p.1291

2021

Volltextzugriff (PDF)

Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains

Neuroscience letters, 2021-05, Vol.754, p.135894-135894, Article 135894

2021

Volltextzugriff (PDF)

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease

Alzheimer's research & therapy, 2014-01, Vol.6 (2), p.16-16

2014

Volltextzugriff (PDF)

Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease

Journal of Alzheimer's disease, 2009-01, Vol.16 (3), p.649

2009

Volltextzugriff (PDF)

Rapid amyloid‐β oligomer and protofibril accumulation in traumatic brain injury

Brain pathology (Zurich, Switzerland), 2018-07, Vol.28 (4), p.451-462

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers

DHA-rich n–3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study

Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia

Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study

Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms

Performance on a pattern separation task by Alzheimer's patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels

Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia

Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls

Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study

Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study

Reduced prostaglandin F2α release from blood mononuclear leukocytes after oral supplementation of ω3 fatty acids: the OmegAD study

Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease

Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody

Transfer of omega‐3 fatty acids across the blood–brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study

Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study

Porous graphitic carbon chromatography–tandem mass spectrometry for the study of isoprostanes in human cerebrospinal fluid

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study

Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trial-The OmegAD Study

Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease

Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease

Rapid amyloid‐β oligomer and protofibril accumulation in traumatic brain injury

Suchergebnisse filtern